- Report
- April 2025
- 89 Pages
Global
From €5317EUR$5,850USD£4,553GBP
- Report
- April 2025
- 175 Pages
Global
From €4081EUR$4,490USD£3,495GBP
- Report
- March 2025
- 200 Pages
Global
From €4081EUR$4,490USD£3,495GBP
- Report
- June 2020
- 753 Pages
Global
From €2999EUR$3,300USD£2,568GBP
- Report
- March 2021
- 102 Pages
Global
From €4090EUR$4,500USD£3,502GBP
- Drug Pipelines
- April 2024
- 250 Pages
Global
From €2727EUR$3,000USD£2,335GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1136EUR$1,250USD£973GBP
- Report
- February 2024
- 111 Pages
Global
From €4317EUR$4,750USD£3,697GBP
- Report
- August 2022
- 120 Pages
Global
From €4317EUR$4,750USD£3,697GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$4,125USD£3,102GBP
- Report
- August 2022
- 68 Pages
Global
From €3181EUR$3,500USD£2,724GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
Azacitidine is a drug used in the treatment of certain types of cancer, such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). It is a pyrimidine analog, which works by inhibiting the growth of cancer cells and inducing apoptosis. Azacitidine is administered intravenously or subcutaneously, and is often used in combination with other drugs.
Azacitidine is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2014. It is used to treat patients who have not responded to other treatments, and is considered a breakthrough therapy for MDS.
The azacitidine market is highly competitive, with several major players in the field. These include Celgene Corporation, Teva Pharmaceuticals, Pfizer, and Novartis. Other companies involved in the market include Merck, Johnson & Johnson, and Bristol-Myers Squibb. Show Less Read more